Therefore, we aimed to investigate the therapeutic effects of CHZ868, a selective JAK2 inhibitor, in combination with CD19 + CAR-T cells against B-ALL. This evidence concerns the gene JAK2 and precursor B-cell acute lymphoblastic leukemia.